Research Status of Alpha-Emitting Radionuclide 225Ac: Preparation and Medical Application

Abstract

Targeted alpha therapy (TAT) is a kind of nuclear medicine treatment based on alpha-emitting radionuclides and tumor-selective carrier molecules for targeted cancer cells. Due to its strong toxicity to targeted cancer cells and relatively less toxic to normal tissues, TAT has been a promising tumor treatment method. Attributed to its suitable half-life (9.9 d), unique decay properties (decay produceing 4α+2β particles), and suitable coordination, 225Ac has become one of the best choice for α nuclides in TAT. Studies have shown that the targeted 225Ac-radiopharmaceuticals exhibit excellent effectiveness on cancer treatment, but the preparation of 225Ac is facing research difficulties. This article summarized the properties of 225Ac nuclide, the status of the preparation process and 225Ac-radiopharmaceuticals for TAT. And prospects were proposed for the production process of 225Ac and its medical application. It is expected that the large-scale production of medical 225Ac will be standardized, and 225Ac-radiopharmaceuticals will be approved for tumor treatment in the future.

Keywords

• tat
• 225ac
• production method